NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NovoCure Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$14.89+0.82 (+5.83%)
Close on Oct 19, 2026
- Market cap
- $1.73B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.11 (+8.06%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
NovoCure Ltd grew revenue 11.0% to $699.19M over the twelve months to Jun 30, 2026. Free cash flow was -$25.43M.
Revenue
$699.19M
+11.0% vs. a year earlier
Operating income
-$154.40M
TTM Q2 2026
Free cash flow
-$25.43M
TTM Q2 2026
EPS, diluted
-$1.30
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.73B
- P/E ratio
- –
- Price to sales
- 2.47
- Price to book
- 5.11
- Dividend yield
- –
- Free cash flow yield
- -1.47%
Fundamentals
- Revenue
- $699.19M
- Net income
- -$148.57M
- EPS, diluted
- -$1.30
- Free cash flow
- -$25.43M
- Book value per share
- $2.91
- Diluted shares
- 116M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$699.19M+11.0% YoY
Gross profit
$532.27M+10.6% YoY
Operating income
-$154.40M
Net income
-$148.57M
EPS, diluted
-$1.30
Free cash flow
-$25.43M
Reported periodTrailing twelve months